| Followers | 258 |
| Posts | 19732 |
| Boards Moderated | 0 |
| Alias Born | 10/03/2004 |
Wednesday, May 26, 2010 10:03:06 PM
You are mischaracterizing both Cox's statements about the PRV and the negotiating principles with big pharma.
The PRV is awarded for final review and must be applied for a minimum of 1 year before the filing of the NDA. So, far, the PRV awards have come in late stage clinical testing, but could possibly come earlier. Eventually, PRVs could be generated in multiples each year, but the system isn't designed for that type of exploitation by a single producers. Nonetheless there should be a shot at 3 or 4 of those in a two year period. Even one would lend $300 million or mnore in company value or cash. Cox didn't go into detail nor did he give specific numbers in the articles I read.
I'm unclear on what you mean by "forward sell." If you mean sell to a big pharma, yes. But to include that in a list of things that could have been done by management as part of your criticism when in fact the strategy doesn't yet exist, makes your proposition preposterous.
The PRV is awarded for final review and must be applied for a minimum of 1 year before the filing of the NDA. So, far, the PRV awards have come in late stage clinical testing, but could possibly come earlier. Eventually, PRVs could be generated in multiples each year, but the system isn't designed for that type of exploitation by a single producers. Nonetheless there should be a shot at 3 or 4 of those in a two year period. Even one would lend $300 million or mnore in company value or cash. Cox didn't go into detail nor did he give specific numbers in the articles I read.
I'm unclear on what you mean by "forward sell." If you mean sell to a big pharma, yes. But to include that in a list of things that could have been done by management as part of your criticism when in fact the strategy doesn't yet exist, makes your proposition preposterous.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM

